Safety and efficacy of tofacitinib for up to 9.5  years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5  mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid a...

Source: Arthritis Research and Therapy - April 5, 2019 Category: Rheumatology Authors: J ürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis, Joel Silverfield, Ketti Terry, Koshika Soma, Chris Mojcik, Ryan DeMasi, Sander Strengholt, Kenneth Kwok, Irina Lazariciu, Lisy Wang and Stanley Cohen Tags: Research article Source Type: research